Suitability of a recombinant Staphylococcus aureus enterotoxin C bovine variant for immunodiagnostics and therapeutic vaccine development

Growth inhibition of Staphylococcus aureus and escherichia coli strains by neutralizing IgY antibodies from ostrich egg yolk

“…Toxigenic S. aureus strains had their growth abrogated in vitro by native antigens of S. aureus (9, 24, 32). Others described antibodies from serum against native SEC (23) and recombinant SEC (26), but this is the first work to describe development of IgY in ostriches immunized with SEC recombinant protein, and tested against growth of S. aureus strains from different origin. Sugita-Konishi et al (24) demonstrated the growth inhibition activity of IgY on SEA producer S. aureus strains.…”

“…The selected recombinant proteins were recSEC and recRAP derived from S. aureus and recEspB and recBFPA from E. coli , previously used by others (2, 26). From each female blood and non-fertilized eggs were collected before and after each immunization step, in order to obtain negative controls.…”

Comparative Opsonic and Protective Activities of Staphylococcus aureus Conjugate Vaccines Containing Native or Deacetylated Staphylococcal Poly- N -Acetyl-β-(1-6)-Glucosamine

“…S. aureus causes diverse infections such as endocarditis, septic arthritis, osteomyelitis, meningitis, skin infections, and abscesses (1,2,7,16,23,27) and there appears to be an increase in the recognition of community-acquired S. aureus infections, often involving methicillin-resistant S. aureus strains (16,27). It is now well appreciated that the emergence of antibiotic resistance among staphylococcal isolates has made the treatment of these infections increasingly difficult, which has amplified the call for new approaches to treat and prevent staphylococcal infections, such as immunotherapy.Ongoing efforts to design vaccines for S. aureus have targeted various virulence factors of this organism, including capsular polysaccharides (CP) (i.e., CP serotypes 5 and 8) (8, 9), cell wall-associated proteins (i.e., clumping factor A, fibronectin binding proteins, and collagen binding protein) (11,36,48), toxins (i.e., alpha-toxin, enterotoxins, and toxic shock syndrome toxin 1) (6,14,15,21,33), and the surface-associated polysaccharide, poly-N-acetyl-␤-(1-6)-glucosamine (PNAG) (25,26,29). PNAG is synthesized by enzymes encoded in the intercellular adhesin (ica) locus (12), which occurs not only in most clinical isolates of S. aureus but also in the majority of clinical isolates of CoNS (28,31,34,53), making PNAG an attractive vaccine candidate.…”

“…Ongoing efforts to design vaccines for S. aureus have targeted various virulence factors of this organism, including capsular polysaccharides (CP) (i.e., CP serotypes 5 and 8) (8, 9), cell wall-associated proteins (i.e., clumping factor A, fibronectin binding proteins, and collagen binding protein) (11,36,48), toxins (i.e., alpha-toxin, enterotoxins, and toxic shock syndrome toxin 1) (6,14,15,21,33), and the surface-associated polysaccharide, poly-N-acetyl-␤-(1-6)-glucosamine (PNAG) (25,26,29). PNAG is synthesized by enzymes encoded in the intercellular adhesin (ica) locus (12), which occurs not only in most clinical isolates of S. aureus but also in the majority of clinical isolates of CoNS (28,31,34,53), making PNAG an attractive vaccine candidate.…”

Involvement of immune response in anti-tumor effects of Staphylococcus Aureus Filtrate Preparation

“…It was reported that SEC is a kind of superantigens (SAgs) (Balaban and Rasooly 2000;de Carvalho Uhl et al 2004), which could stimulate abnormally large number of T-cells and were able to induce T-cell proliferation at nanomolar concentrations (Balaban and Rasooly 2000;Ferens et al 1998;Haller et al 2002;Lamphear et al 1998). The activated T-lymphocytes could enhance the secreting of downstream cytokines such as interleukin-2 (IL-2), IL-6, gamma interferon (IFN-) and tumor necrosis factor alpha (TNF-), which have a close relationship with tumor immunity (Lamphear et al 1998;Komine et al 2004;Li et al 2003).…”